2-环丙基乙脒 | 779261-94-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-环丙基乙脒
• 英文名称: cyclopropylethaneimidamide
• 英文别名: 2-cyclopropylethanamidine；Cyclopropylacetamidin；2-Cyclopropyl-acetamidine；2-cyclopropylethanimidamide
• CAS: 779261-94-8
• 化学式: C₅H₁₀N₂
• 分子量: 98.1478
• InChiKey: QDKGGUVUUBZSOR-UHFFFAOYSA-N

物化性质

• 沸点：
  157.0±23.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.9
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  2-环丙基乙脒 在 sodium ethanolate 、 N,N-二乙基苯胺 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 生成 N-[6-chloro-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinyl]-N-cyclopropylamine
  参考文献：
  名称：

  First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives

  摘要：

  SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.006

文献信息

• Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith
  申请人：McKenna M. Jeffrey

  公开号：US20080004271A1

  公开（公告）日：2008-01-03

  Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula I: and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R 1 , R 2 , R 3 , R 4 , n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.

  本文提供具有TNFα和/或PDE4和/或B-RAF抑制活性的化合物及其组合物。特别地，本文提供了式I的化合物：以及其药学上可接受的盐、溶剂化合物、水合物、包合物、立体异构体、多晶形和前药，其中Ar、R1、R2、R3、R4、n和Z如本文所述。此外，本文提供了通过向患者给予一种或多种TNFα和/或PDE4和/或B-RAF抑制剂来治疗或预防各种疾病和疾病的方法。特别地，本文提供了通过向患者给予一种或多种TNFα和/或PDE4和/或B-RAF抑制剂来预防或治疗癌症、炎症性疾病、认知和记忆障碍和自身免疫性疾病或其一种或多种症状的方法。
• [EN] INHIBITORS OF TNFa, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH<br/>[FR] INHIBITEURS DE TNFa, DE PDE4 ET DE B-RAF, COMPOSITIONS COMPRENANT CES INHIBITEURS ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：SIGNAL PHARM LLC

  公开号：WO2007084560A3

  公开（公告）日：2007-09-20
• First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives
  作者：Laurent Provins、Bernard Christophe、Pierre Danhaive、Jacques Dulieu、Véronique Durieu、Michel Gillard、Florence Lebon、Sébastien Lengelé、Luc Quéré、BerendJan van Keulen

  DOI：10.1016/j.bmcl.2006.01.006

  日期：2006.4

  SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.